Back to results
US 2023/0263779 A1Published application
Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
AssigneeAbraxis BioScience, LLC
InventorNeil P. DESAI
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for the treatment of a solid tumor by administering compositions comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug, e.g., sirolimus or a derivative thereof) and an albumin in combination with compositions comprising a second therapeutic agent.
Claims29
1:
- A method of treating a solid tumor in an individual, comprising administering to the individual:
- a) an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin, and b) an effective amount of a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of an immunomodulator, a histone deacetylase inhibitor, and a kinase inhibitor.
2:
- The method of claim 1, wherein the solid tumor is bladder cancer, renal cell carcinoma, soft-tissue sarcoma, or melanoma.
3:
- The method of claim 1, wherein the solid tumor is relapsed or refractory to a standard therapy for the solid tumor.
4:
- The method of claim 1, wherein the amount of the mTOR inhibitor in the mTOR inhibitor nanoparticle composition is from about 10 mg/m2 to about 150 mg/m2.
5-6. (canceled)
7:
- The method of claim 1, wherein the mTOR inhibitor nanoparticle composition is administered weekly.
(canceled)
9:
- The method of claim 1, wherein the mTOR inhibitor nanoparticle composition and the second therapeutic agent are administered sequentially to the individual.
10:
- The method of claim 1, wherein the mTOR inhibitor nanoparticle composition and the second therapeutic agent are administered simultaneously to the individual.
11:
- The method of claim 1, wherein the mTOR inhibitor is a limus drug.
12:
- The method of claim 11, wherein the limus drug is sirolimus.
13:
- The method of claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than about 150 nm.
(canceled)
15:
- The method of claim 1, wherein the weight ratio of the albumin to the mTOR inhibitor in the nanoparticle composition is no greater than about 9:1.
16:
- The method of claim 1, wherein the nanoparticles comprise the mTOR inhibitor associated with the albumin.
17-18. (canceled)
19:
- The method of claim 1, wherein the mTOR inhibitor nanoparticle composition is administered intravenously.
20:
- The method of claim 1, wherein the individual is human.
21:
- The method of claim 1, further comprising selecting the individual for treatment based on the presence of at least one mTOR-activating aberration.
22-23. (canceled)
24:
- The method of claim 1, wherein the second therapeutic agent is an immunomodulator.
(canceled)
26:
- The method of claim 24, wherein the immunomodulator is an immune checkpoint inhibitor or an anti-PD-1 antibody.
27-29. (canceled)
30:
- The method of claim 1, wherein the second therapeutic agent is a histone deacetylase inhibitor.
31-33. (canceled)
34:
- The method of claim 1, wherein the second therapeutic agent is a kinase inhibitor.
35:
- The method of claim 34, wherein the kinase inhibitor is a tyrosine kinase inhibitor.
36-44. (canceled)
Dependencies are inferred from the claim text.